Abstract 5929
Background
Data for metastatic soft tissue sarcoma (STS) is sparse from developing countries. Pazopanib has demonstrated promising activity in the management of this disease. This study was carried out in the dedicated sarcoma medical oncology clinic in a tertiary referral center of Western India.
Methods
This is a retrospective analysis of prospective database from adult sarcoma medical oncology clinic at Tata Memorial Center, Mumbai from January 2035 to December 2018. The patients were provided holistic care through involvement of palliative care team, government fundings, local NGOs and sarcoma support groups. All statistical calculations were done using SPSS version 20.
Results
A total of 314 patients diagnosed with metastatic STS were registered in the dedicated medical oncology sarcoma clinic, 72% were males and median age 46 (16-79) years. Out of 314 patients, 60 (19%) patients received Pazopanib at some point of time during their treatment. Most common histology was synovial sarcoma (28%), leiomyosarcoma (26%), unspecified high grade spindle cell sarcoma (19%) and alveolar soft part sarcoma (12%). The median follow up duration was 18 (4-41) months. Median lines of prior therapy were 2 (0-2). Among 42 evaluable patients, there were 24% partial responses, 48% stable disease and 28% progressive disease. Median progression free survival was 5 (95% CI 3-7.3) months and median overall survival was 11 (95% CI 6.8-16.2) months. Important adverse events (>grade 1) included hand foot syndrome (10%), diarrhea (10%), hypothyroidism (10%), fatigue (8%) and hyperbilirubinemia/transaminitis (8%). Notably 50% patients required dose reduction and median dose was 600(200-800) mg daily.
Conclusions
Pazopanib was found to be a feasible treatment option for metastatic STS in India with internationally comparable outcomes. Median tolerated dose was lower than the standard 800 mg dose. Outcomes could be improved due to dedicated clinic with availability of targeted therapy with government help and local NGOs. This model of providing holistic care can be replicated in rare tumors in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract